NMRA PRESS-RELEASE SEC Filing Analysis

Final — all horizons settled through T+60d

NMRA ▼ -43.55% at T+60d

NEUTRAL call ✗ call lost -43.55% · α vs SPY -54.04% · entry $2.87 → $1.62

Last close $1.62 (close Jun 8) · -43.55% from $2.87 entry

Entry anchored
Mar 13, 03:59 PM ET
via Databento tick

T+1d

-1.39%

call -1.39% · α -1.67%

$2.83

settled 3mo ago

T+5d

-13.94%

call -13.94% · α -11.90%

$2.47

settled 3mo ago

T+20d

-29.27%

call -29.27% · α -33.05%

$2.03

settled 8w ago

T+60d

-43.55%

call -43.55% · α -54.04%

$1.62

settled in 6h

Price Chart

Loading chart...

Executive Summary

Neumora Therapeutics announced it will report its Q4 and full-year 2025 financial results on March 30, 2026, via a live webcast and conference call. No financial data was released in this announcement — it is solely a press release notifying investors of an upcoming earnings event.

Actionable Insight

Traders should prepare for potential volatility following the March 30 earnings release, particularly around pipeline progress, cash runway, and R&D spend. Monitor for updates on clinical trial timelines and funding needs.

Key Facts

Neumora Therapeutics will report Q4 and full-year 2025 financial results on March 30, 2026.
Event will include a conference call and live webcast at 8:00 a.m. ET.
No financial results or business updates were disclosed in this press release.
Replay will be available on the company's website for up to 30 days.

Financial Impact

No financial data disclosed — impact to be determined at earnings release.

Risk Factors

Biotech earnings can be volatile, especially for clinical-stage companies with no revenue.
Potential for dilutive financing if cash runway is short and no partnerships are announced.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3256107

3 reports for NMRA

T+1T+5T+20T+60

Filters

Reports for NMRA — sortable, filterable
	Type				Now
Apr 17, 2026 7w ago	DEFA14A NEUTRAL ★ 2/10	$2.19 $1.77	▼ −19.18%	▼ −23.38%	$1.62 (−26.03%)
Mar 30, 2026 10w ago	Press Release MIXED ★ 5/10	$1.93 $2.25	▲ +16.58%	▲ +3.98%	$1.62 (−16.06%)
Mar 16, 2026 12w ago	Press Release NEUTRAL ★ 3/10	$2.87 $2.03	▼ −29.27%	▼ −33.05%	$1.62 (−43.55%)

US Market Status

Market Closed — Opens in 7h 23m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access